首页> 外文期刊>International journal of antimicrobial agents >Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains
【24h】

Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains

机译:美罗培南和哌拉西林在危重患者留置引流管中的药代动力学

获取原文
获取原文并翻译 | 示例
           

摘要

Meropenem and piperacillin are two commonly prescribed antibiotics in critically ill surgical patients. To date, the pharmacokinetics of these antibiotics in the presence of indwelling abdominal surgical drains is poorly defined. This was a prospective pharmacokinetic study of meropenem and piperacillin. Serial plasma, urine and surgical drain fluid samples were collected over one dosing interval of antibiotic treatment in ten patients (meropenem, n = 5; piperacillin n = 5). Drug concentrations were measured using a validated high-performance liquid chromatography assay. Median (interquartile range) pharmacokinetic parameter estimates for meropenem were as follows: area under concentration-time curve (AUC), 128.7 mg h/L (95.3-176.7 mg h/L); clearance (CL), 5.7 L/h (5.1-10.5 L/h); volume of distribution (V_d), 0.41 L/kg (0.35-0.56 L/kg); AUC ratio (drain:plasma), 0.2 (0.1-0.2); and calculated antibiotic clearance via surgical drain, 3.8% (2.8-5.4%). For piperacillin, unbound pharmacokinetic results were as follows; AUC, 344.3 mg h/L (341.1-348.4 mg h/L); CL, 13.1 L/h (12.9-13.2 L/h); V_d, 0.63 L/kg (0.38-1.28 L/kg); AUC ratio (drain:plasma), 0.2 (0.2-0.3); and calculated antibiotic clearance via surgical drain 8.2% (3.3-14.0%). A linear correlation was present between the percentage of antibiotic cleared through the drain and the volume of surgical drain fluid output for meropenem (r~2 = 0.89; P = 0.05) and piperacillin (r~2 = 0.63; P = 0.20). Meropenem and piperacillin have altered pharmacokinetics in critically ill patients with indwelling surgical drains. We propose that only when very high drain fluid output is present (>1000 mL/day) would an additional dose of antibiotic be necessary.
机译:美罗培南和哌拉西林是危重手术患者中常用的两种抗生素。迄今为止,在存在留置的腹部手术引流管的情况下,这些抗生素的药代动力学尚不清楚。这是美洛培南和哌拉西林的前瞻性药代动力学研究。在十个患者的抗生素治疗的一个给药间隔内收集了一系列血浆,尿液和外科手术引流液样品(美洛培南,n = 5;哌拉西林n = 5)。使用经过验证的高效液相色谱法测量药物浓度。美罗培南的中位(四分位间距)药代动力学参数估计如下:浓度-时间曲线下面积(AUC),128.7 mg h / L(95.3-176.7 mg h / L);间隙(CL),5.7升/小时(5.1-10.5升/小时);分配体积(V_d),0.41 L / kg(0.35-0.56 L / kg); AUC比(Drain:Plasma)为0.2(0.1-0.2);计算出的通过手术引流的抗生素清除率为3.8%(2.8-5.4%)。对于哌拉西林,未结合的药代动力学结果如下: AUC,344.3 mg h / L(341.1-348.4 mg h / L); CL,13.1 L / h(12.9-13.2 L / h); V_d,0.63 L / kg(0.38-1.28 L / kg); AUC比(Drain:Plasma)为0.2(0.2-0.3);并计算出通过手术引流的抗生素清除率为8.2%(3.3-14.0%)。美罗培南(r〜2 = 0.89; P = 0.05)和哌拉西林(r〜2 = 0.63; P = 0.20)的排泄物清除率与手术排泄液输出量之间存在线性关系。美罗培南和哌拉西林已改变了留有外科引流管的危重患者的药代动力学。我们建议仅当排泄液输出量很高(> 1000 mL /天)时,才需要额外剂量的抗生素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号